vs
渤健（BIIB）与赛莱默（XYL）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是赛莱默的1.1倍（$2.3B vs $2.1B），赛莱默净利率更高（8.9% vs -2.1%，领先11.0%），赛莱默同比增速更快（2.7% vs -7.1%），过去两年渤健的营收复合增速更高（-0.2% vs -1.0%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
该文本为植物学对木质部的定义说明，并非赛莱默公司（Xylem Inc.）的企业业务介绍。Xylem Inc.是一家专注于水技术与解决方案的全球企业，提供水务基础设施、水环境治理等相关设备与服务。
BIIB vs XYL — 直观对比
营收规模更大
BIIB
是对方的1.1倍
$2.1B
营收增速更快
XYL
高出9.8%
-7.1%
净利率更高
XYL
高出11.0%
-2.1%
两年增速更快
BIIB
近两年复合增速
-1.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.1B |
| 净利润 | $-48.9M | $189.0M |
| 毛利率 | 78.3% | 37.8% |
| 营业利润率 | -2.5% | 11.5% |
| 净利率 | -2.1% | 8.9% |
| 营收同比 | -7.1% | 2.7% |
| 净利润同比 | -118.3% | 13.2% |
| 每股收益（稀释后） | $-0.35 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBXYL
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.3B | $2.4B | ||
| Q3 25 | $2.5B | $2.3B | ||
| Q2 25 | $2.6B | $2.3B | ||
| Q1 25 | $2.4B | $2.1B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.5B | $2.2B |
净利润BIIBXYL
| Q1 26 | — | $189.0M | ||
| Q4 25 | $-48.9M | $335.0M | ||
| Q3 25 | $466.5M | $227.0M | ||
| Q2 25 | $634.8M | $226.0M | ||
| Q1 25 | $240.5M | $169.0M | ||
| Q4 24 | $266.7M | $326.0M | ||
| Q3 24 | $388.5M | $217.0M | ||
| Q2 24 | $583.6M | $194.0M |
毛利率BIIBXYL
| Q1 26 | — | 37.8% | ||
| Q4 25 | 78.3% | 38.9% | ||
| Q3 25 | 73.4% | 38.9% | ||
| Q2 25 | 77.1% | 38.8% | ||
| Q1 25 | 74.1% | 37.1% | ||
| Q4 24 | 76.2% | 38.0% | ||
| Q3 24 | 74.1% | 37.3% | ||
| Q2 24 | 77.8% | 37.8% |
营业利润率BIIBXYL
| Q1 26 | — | 11.5% | ||
| Q4 25 | -2.5% | 14.7% | ||
| Q3 25 | 22.0% | 14.7% | ||
| Q2 25 | 28.1% | 13.3% | ||
| Q1 25 | 12.8% | 11.2% | ||
| Q4 24 | 11.9% | 11.8% | ||
| Q3 24 | 18.3% | 13.3% | ||
| Q2 24 | 28.3% | 11.7% |
净利率BIIBXYL
| Q1 26 | — | 8.9% | ||
| Q4 25 | -2.1% | 14.0% | ||
| Q3 25 | 18.4% | 10.0% | ||
| Q2 25 | 24.0% | 9.8% | ||
| Q1 25 | 9.9% | 8.2% | ||
| Q4 24 | 10.9% | 14.5% | ||
| Q3 24 | 15.8% | 10.3% | ||
| Q2 24 | 23.7% | 8.9% |
每股收益（稀释后）BIIBXYL
| Q1 26 | — | $0.79 | ||
| Q4 25 | $-0.35 | $1.37 | ||
| Q3 25 | $3.17 | $0.93 | ||
| Q2 25 | $4.33 | $0.93 | ||
| Q1 25 | $1.64 | $0.69 | ||
| Q4 24 | $1.82 | $1.33 | ||
| Q3 24 | $2.66 | $0.89 | ||
| Q2 24 | $4.00 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $808.0M |
| 总债务越低越好 | $6.3B | $1.9B |
| 股东权益账面价值 | $18.3B | $11.0B |
| 总资产 | $29.4B | $17.0B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资BIIBXYL
| Q1 26 | — | $808.0M | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $989.0M | ||
| Q2 24 | — | $815.0M |
总债务BIIBXYL
| Q1 26 | — | $1.9B | ||
| Q4 25 | $6.3B | $2.0B | ||
| Q3 25 | $6.3B | $2.0B | ||
| Q2 25 | $6.3B | $2.0B | ||
| Q1 25 | $4.5B | $2.0B | ||
| Q4 24 | $6.3B | $2.0B | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBXYL
| Q1 26 | — | $11.0B | ||
| Q4 25 | $18.3B | $11.5B | ||
| Q3 25 | $18.2B | $11.2B | ||
| Q2 25 | $17.6B | $11.1B | ||
| Q1 25 | $17.0B | $10.8B | ||
| Q4 24 | $16.7B | $10.6B | ||
| Q3 24 | $16.4B | $10.6B | ||
| Q2 24 | $15.9B | $10.3B |
总资产BIIBXYL
| Q1 26 | — | $17.0B | ||
| Q4 25 | $29.4B | $17.6B | ||
| Q3 25 | $29.2B | $17.3B | ||
| Q2 25 | $28.3B | $17.2B | ||
| Q1 25 | $28.0B | $16.6B | ||
| Q4 24 | $28.0B | $16.5B | ||
| Q3 24 | $28.3B | $16.0B | ||
| Q2 24 | $26.8B | $15.8B |
负债/权益比BIIBXYL
| Q1 26 | — | 0.18× | ||
| Q4 25 | 0.34× | 0.17× | ||
| Q3 25 | 0.35× | 0.18× | ||
| Q2 25 | 0.36× | 0.18× | ||
| Q1 25 | 0.27× | 0.19× | ||
| Q4 24 | 0.38× | 0.19× | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | — |
| 自由现金流经营现金流 - 资本支出 | $468.0M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.9% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBXYL
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $543.0M | ||
| Q3 25 | $1.3B | $360.0M | ||
| Q2 25 | $160.9M | $305.0M | ||
| Q1 25 | $259.3M | $33.0M | ||
| Q4 24 | $760.9M | $575.0M | ||
| Q3 24 | $935.6M | $311.0M | ||
| Q2 24 | $625.8M | $288.0M |
自由现金流BIIBXYL
| Q1 26 | — | — | ||
| Q4 25 | $468.0M | $460.0M | ||
| Q3 25 | $1.2B | $281.0M | ||
| Q2 25 | $134.3M | $207.0M | ||
| Q1 25 | $222.2M | $-38.0M | ||
| Q4 24 | $721.6M | $475.0M | ||
| Q3 24 | $900.6M | $237.0M | ||
| Q2 24 | $592.3M | $215.0M |
自由现金流率BIIBXYL
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 19.2% | ||
| Q3 25 | 48.4% | 12.4% | ||
| Q2 25 | 5.1% | 9.0% | ||
| Q1 25 | 9.1% | -1.8% | ||
| Q4 24 | 29.4% | 21.1% | ||
| Q3 24 | 36.5% | 11.3% | ||
| Q2 24 | 24.0% | 9.9% |
资本支出强度BIIBXYL
| Q1 26 | — | 4.2% | ||
| Q4 25 | 1.9% | 3.5% | ||
| Q3 25 | 1.8% | 3.5% | ||
| Q2 25 | 1.0% | 4.3% | ||
| Q1 25 | 1.5% | 3.4% | ||
| Q4 24 | 1.6% | 4.4% | ||
| Q3 24 | 1.4% | 3.5% | ||
| Q2 24 | 1.4% | 3.4% |
现金转化率BIIBXYL
| Q1 26 | — | — | ||
| Q4 25 | — | 1.62× | ||
| Q3 25 | 2.73× | 1.59× | ||
| Q2 25 | 0.25× | 1.35× | ||
| Q1 25 | 1.08× | 0.20× | ||
| Q4 24 | 2.85× | 1.76× | ||
| Q3 24 | 2.41× | 1.43× | ||
| Q2 24 | 1.07× | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
XYL
| Revenue from products | $1.8B | 83% |
| Revenue from services | $368.0M | 17% |
